Close Menu

NEW YORK (GenomeWeb) – Abbott reported Wednesday morning that first quarter sales in its Diagnostics business grew 4 percent year over year, driven by strong growth in core laboratory and point-of-care sales.

For the three months ended March 31, Abbott reported overall Q1 revenues of $6.34 billion, up 30 percent on a reported basis from Q1 last year, and up 3 percent on a comparable basis accounting for the acquisition of St. Jude Medical closed in January. The company beat the consensus Wall Street estimate of $6.15 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.